Skip Navigation



JAC Advance Access published online on November 10, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki399
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/1/135    most recent
dki399v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Warn, P. A.
Right arrow Articles by Denning, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warn, P. A.
Right arrow Articles by Denning, D. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received July 20, 2005
Revised September 19, 2005
Accepted October 5, 2005

Brief report

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp

Peter A. Warn 1*, Andrew Sharp 1, and David W. Denning 2

1 School of Medicine, 1.800 Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK
2 School of Medicine, 1.800 Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK; Wythenshawe Hospital, Southmoor Road, Manchester M23 9PL, UK

* To whom correspondence should be addressed.
Peter A. Warn, E-mail: peter.warn{at}manchester.ac.uk


  Abstract

Objectives: BAL4815 is the active component of the antifungal triazole agent BAL8557 (the water-soluble prodrug). We compared the in vitro activity of BAL4815 with that of itraconazole, voriconazole, caspofungin and amphotericin B against 118 isolates of Aspergillus comprising four different species (fumigatus, terreus, flavus and niger); the isolates were pre-selected to include 16 isolates demonstrating in vitro resistance to other agents.

Methods: Susceptibilities were determined for BAL4815, amphotericin B, itraconazole and voriconazole using the microdilution plate modification of the NCCLS M38-A method with RPMI 1640 buffered to pH 7.0 with MOPS; for caspofungin the method was modified using incubation in a gas mixture of 1% O2/5% CO2/94% N2 to aid reading. MFCs (≥99% kill) were also determined for all drugs other than caspofungin.

Results: For all isolates, geometric mean (GM) MIC values and ranges (in mg/L) were: BAL4815, 0.620 and 0.125-2.0; itraconazole, 0.399 and 0.063->8.0; voriconazole, 0.347 and 0.125-8.0; caspofungin, 0.341 and 0.125-4.0; amphotericin B, 0.452 and 0.06-4.0. No significant differences in susceptibility to BAL4815 were seen between species and in contrast to itraconazole no isolates demonstrated MICs >2.0 mg/L. For all isolates, GM MFC values and ranges (in mg/L) were: BAL4815, 1.68 and 0.25->8.0; itraconazole, 1.78 and 0.06->8.0; voriconazole, 1.09 and 0.25->8.0; amphotericin B, 0.98 and 0.25->4.0.

Conclusions: BAL4815 demonstrated promising antifungal activity against all four Aspergillus species in vitro including strains resistant to itraconazole, caspofungin or amphotericin B.

Keywords: antifungal susceptibility; itraconazole; voriconazole; caspofungin; amphotericin B.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Perkhofer, V. Lechner, and C. Lass-Florl
In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1645 - 1647.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Majithiya, A. Sharp, A. Parmar, D. W. Denning, and P. A. Warn
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei
J. Antimicrob. Chemother., January 1, 2009; 63(1): 161 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. R. Thompson III, A. W. Fothergill, N. P. Wiederhold, A. C. Vallor, B. L. Wickes, and T. F. Patterson
Evaluation of Etest Method for Determining Isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans
Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2959 - 2961.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. M. de la Escalera, A. I. Aller, E. Lopez-Oviedo, A. Romero, A. I. Martos, E. Canton, J. Peman, P. G. Martos, and E. Martin-Mazuelos
Activity of BAL 4815 against filamentous fungi
J. Antimicrob. Chemother., May 1, 2008; 61(5): 1083 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Guinea, T. Pelaez, S. Recio, M. Torres-Narbona, and E. Bouza
In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species
Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1396 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. C. Pasqualotto and D. W. Denning
New and emerging treatments for fungal infections
J. Antimicrob. Chemother., January 1, 2008; 61(suppl_1): i19 - i30.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Meletiadis, C. Antachopoulos, T. Stergiopoulou, S. Pournaras, E. Roilides, and T. J. Walsh
Differential Fungicidal Activities of Amphotericin B and Voriconazole against Aspergillus Species Determined by Microbroth Methodology
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3329 - 3337.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Seifert, U. Aurbach, D. Stefanik, and O. Cornely
In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates
Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1818 - 1821.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. A. Warn, A. Sharp, J. Mosquera, J. Spickermann, A. Schmitt-Hoffmann, M. Heep, and D. W. Denning
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1198 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
B. Capitano, B. A. Potoski, S. Husain, S. Zhang, D. L. Paterson, S. M. Studer, K. R. McCurry, and R. Venkataramanan
Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen.
Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1878 - 1880.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.